title: Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.
authors.forename: Ruben
authors.initials: R
authors.lastname: Mesa
authors.forename: Catriona
authors.initials: C
authors.lastname: Jamieson
authors.forename: Ravi
authors.initials: R
authors.lastname: Bhatia
authors.forename: Michael W
authors.initials: MW
authors.lastname: Deininger
authors.forename: Aaron T
authors.initials: AT
authors.lastname: Gerds
authors.forename: Ivana
authors.initials: I
authors.lastname: Gojo
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
authors.forename: Krishna
authors.initials: K
authors.lastname: Gundabolu
authors.forename: Gabriela
authors.initials: G
authors.lastname: Hobbs
authors.forename: Rebecca B
authors.initials: RB
authors.lastname: Klisovic
authors.forename: Patricia
authors.initials: P
authors.lastname: Kropf
authors.forename: Sanjay R
authors.initials: SR
authors.lastname: Mohan
authors.forename: Stephen
authors.initials: S
authors.lastname: Oh
authors.forename: Eric
authors.initials: E
authors.lastname: Padron
authors.forename: Nikolai
authors.initials: N
authors.lastname: Podoltsev
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Pollyea
authors.forename: Raajit
authors.initials: R
authors.lastname: Rampal
authors.forename: Lindsay A M
authors.initials: LA
authors.lastname: Rein
authors.forename: Bart
authors.initials: B
authors.lastname: Scott
authors.forename: David S
authors.initials: DS
authors.lastname: Snyder
authors.forename: Brady L
authors.initials: BL
authors.lastname: Stein
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.forename: Martha
authors.initials: M
authors.lastname: Wadleigh
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
authors.forename: Mary Anne
authors.initials: MA
authors.lastname: Bergman
authors.forename: Kristina M
authors.initials: KM
authors.lastname: Gregory
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D037282:Calreticulin / Q000235:genetics / Q000378:metabolism; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism; D008495:Medical Oncology / Q000592:standards*; D009154:Mutation; D010677:Philadelphia Chromosome; D011087:Polycythemia Vera / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D015995:Prevalence; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D011788:Quality of Life; D053628:Receptors, Thrombopoietin / Q000235:genetics / Q000378:metabolism; D018570:Risk Assessment; D015398:Signal Transduction; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy
chemical_list: C576483:CALR protein, human; D037282:Calreticulin; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2